CeriBell (CBLL) Projected to Post Earnings on Tuesday

CeriBell (NASDAQ:CBLL) is expected to be posting its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect CeriBell to post earnings of ($0.43) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

CeriBell Stock Down 0.9%

CBLL opened at $19.77 on Tuesday. The firm’s 50 day simple moving average is $21.39 and its two-hundred day simple moving average is $15.91. The company has a market capitalization of $733.47 million, a PE ratio of -13.09 and a beta of 1.03. CeriBell has a 1-year low of $10.01 and a 1-year high of $26.04. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12.

Insiders Place Their Bets

In related news, Director Josef Parvizi sold 25,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $22.94, for a total value of $573,500.00. Following the completion of the transaction, the director directly owned 747,652 shares of the company’s stock, valued at $17,151,136.88. This trade represents a 3.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CTO Raymond Woo sold 11,112 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $21.18, for a total value of $235,352.16. Following the sale, the chief technology officer directly owned 167,317 shares in the company, valued at approximately $3,543,774.06. This trade represents a 6.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 369,656 shares of company stock valued at $7,281,615. 20.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CeriBell

Large investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd boosted its holdings in CeriBell by 3,971.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares during the last quarter. Deutsche Bank AG lifted its holdings in CeriBell by 1.7% in the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell during the third quarter worth about $33,000. Finally, Sei Investments Co. lifted its stake in CeriBell by 7.1% in the 3rd quarter. Sei Investments Co. now owns 50,454 shares of the company’s stock worth $580,000 after purchasing an additional 3,365 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on CBLL shares. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. JPMorgan Chase & Co. lowered their price target on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. BTIG Research reissued a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. Raymond James Financial started coverage on shares of CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price objective on the stock. Finally, Canaccord Genuity Group upped their target price on shares of CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.